Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/52057
Campo DC Valoridioma
dc.contributor.authorWägner, Ana M.en_US
dc.contributor.authorPérez, Antonioen_US
dc.contributor.authorCalvo, Fernandoen_US
dc.contributor.authorBonet, Rosaen_US
dc.contributor.authorCastellvi, Agustinaen_US
dc.contributor.authorOrdóñez, Jordien_US
dc.date.accessioned2018-11-25T17:04:53Z-
dc.date.available2018-11-25T17:04:53Z-
dc.date.issued1999en_US
dc.identifier.issn0149-5992en_US
dc.identifier.urihttp://hdl.handle.net/10553/52057-
dc.description.abstractObjective: Apolipoprotein(B) [apo(B)] reflects the total mass of atherogenic particles (VLDL, IDL, and LDL), and its increase is associated with cardiovascular disease independently of LDL cholesterol (LDLc) levels. Apo(B) determination has been recently standardized, but attention to regional reference limits is advisable. Our aim was to analyze the frequency of dyslipidemic phenotypes, including those dependent on increased apo(B) in normocholesterolemic type 2 diabetic patients. Research design and methods: A total of 100 consecutively seen type 2 diabetic patients (63 men, 37 women; aged 59 +/- 11 years) were included, after excluding those on lipid-lowering therapy. Apo(B) cutoff (1.1 g/l) was obtained from a group of normolipidemic (47 men, 21 women) control subjects, and LDLc, triglycerides, and HDL cholesterol (HDLc) cutoff points were those from the National Cholesterol Education Program guidelines. LDLc levels were obtained by ultracentrifugation if triglyceride levels were > 3.45 mmol/l; otherwise, they were calculated (Friedwald). Apo(B) levels were measured by immunoturbidimetry. Results: Normocholesterolemia (LDLc < 4.13 mmol/l) appeared in 75 of the 100 patients, of whom 55 were normo- and 20 hypertriglyceridemic. Hyperapolipoprotein(B) [hyperapo(B)] was the most frequent lipid disorder, present in 34 (45%) of the normocholesterolemic patients (22 normo- and 12 hypertriglyceridemic). Low HDLc levels were more prevalent (53%) in patients with hyperapo(B) than in the rest (24%). Conclusions: Hyperapo(B) was found in almost half of the normocholesterolemic type 2 diabetic patients and was frequently associated with low HDLc levels and hypertriglyceridemia. Thus, given its independent association with cardiovascular disease and that it identifies high-risk phenotypes in normocholesterolemic diabetic patients apo(B) should be used to evaluate the lipidic pattern of these patients.en_US
dc.languageengen_US
dc.relation.ispartofDiabetes Careen_US
dc.sourceDiabetes Care[ISSN 0149-5992],v. 22(5), p. 812-817 (Mayo 1999)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320502 Endocrinologíaen_US
dc.subject.otherApolipoprotein (B)en_US
dc.subject.otherLDL cholesterolen_US
dc.subject.otherTriglyceridesen_US
dc.subject.otherNormocholesterolemiaen_US
dc.titleApolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patientsen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.2337/diacare.22.5.812en_US
dc.identifier.scopus0345711503-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid7402509742-
dc.contributor.authorscopusid7101900838-
dc.contributor.authorscopusid6701846436-
dc.contributor.authorscopusid6701668294-
dc.contributor.authorscopusid7005297613-
dc.description.lastpage817en_US
dc.description.firstpage812en_US
dc.relation.volume22en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.date.coverdateMayo 1999en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr5,076-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

66
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

56
actualizado el 17-nov-2024

Visitas

63
actualizado el 21-sep-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.